Celldex Therapeutics reported third quarter 2026 results with a net loss of US$75.56 million and basic loss per share of US$0.96, alongside a universal shelf registration covering common and preferred stock, warrants, depositary shares and units. The combination of widening losses and a fresh universal shelf registration highlights the pressure on Celldex Therapeutics to secure funding while it continues to invest heavily in its antibody pipeline without meaningful current revenue. We will...
Celldex Therapeutics has seen a mixed share price story in recent years, and that uneven record puts the spotlight on whether the current market value still lines up with what its balance sheet supports. With fresh shareholder litigation headlines now in the mix, the question for you is how much of today’s price rests on expectations that sit beyond the company’s book value. Over the past 5 years the stock has fallen 41.9%, which puts long term holders squarely on the issue of whether the...
Celldex's recent Phase 3 barzolvolimab trials in chronic spontaneous urticaria met endpoints, but the market reaction was negative. Read more on CLDX stock here.
Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
Celldex Therapeutics (NASDAQ:CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the pr
Celldex Therapeutics (NASDAQ:CLDX) shares gained 8% on Tuesday after the company reported positive topline results from two Phase 3 trials evaluating barzolvolimab in patients with chronic spontaneous urticaria (CSU). Both EMBARQ-CSU1 and EMBARQ-CSU2 met their primary endpoints and all key secondary endpoints, demonstrating statistically significant improvements in disease activity compared with placebo.
Celldex (CLDX) stock sank after the company posted Phase 3 trial data for its hives therapy. Read more here.
Celldex Therapeutics' (CLDX) two Phase 3 trials of barzolvolimab in patients with chronic spontaneou
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET. The webcast of the presentation will be available on the “Events and Presentations” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons in immunology to deliver
This is the newest page. Registered accounts read further back.